83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Filed with ASX · · 3 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
- FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
- FDA Accepts BLA for RYONCIL and Agrees to Priority Review
- Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
- Mesoblast Provides Half Year Results and Corporate Update
Later from Mesoblast
- Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment
- MSB Completes Financing For Covid-19 ARDS Manufacturing
- Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
- S&P DJI Announces June 2020 Quarterly Rebalance
- FDA Advisory Committee Sets Review Date for Remestemcel-L
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast